INR control calculation: Comparison of Dutch and international methods

Netherlands Journal of Medicine

Volumn 71, Issue 4, 2013, Pages 194-198

  Bezemer, I D ^a   Roemer, W H ^b   Penning van Beest, F J A ^a   van Eekelen, E ^c   Kramer, M H H ^d  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c Thrombosis Service Region Eindhoven   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anticoagulants; Atrial fibrillation; INR; TTR; Vitamin K antagonists

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; PHENPROCOUMON;

ADULT; AGED; ARTICLE; CALCULATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DESCRIPTIVE RESEARCH; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MEASUREMENT;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; NETHERLANDS; RETROSPECTIVE STUDIES; STROKE; THROMBOSIS; TREATMENT OUTCOME;

EID: 84878445051     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. van Zwieten PA, Hendriks MGC. Nieuwe oraal toepasbare anticoagulantia- thrombine-inhibitoren en Factor Xa antagonisten. Ned Tijdschr Orthopaed. 2010;17:4-7
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151
3. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363:1875-1876
4. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992
5. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891
6. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029-2037
7. van Geest-Daalderop JH, Sturk A, Levi M, Adriaansen HJ. [Extent and quality of anti-coagulation treatment with coumarin derivatives by the Dutch Thrombosis Services]. Omvang en kwaliteit van de antistollingsbehandeling met cumarinederivaten door de Nederlandse trombosediensten. Ned Tijdschr Geneeskd. 2004;148:730-735
8. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236-239
9. Samenvatting Medische Jaarverslagen. Federatie van Nederlandse Trombosediensten, 2007
10. Samenvatting Medische Jaarverslagen. Federatie van Nederlandse Trombosediensten, 2008
11. Samenvatting Medische Jaarverslagen. Federatie van Nederlandse Trombosediensten, 2009
12. Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-intherapeutic range. J Thomb Thrombolysis. 2003;15:213-221
13. van der Meer FJM. Verbetering van de kwaliteit van antistollingsbehandeling met vitamine K-antagonisten. Ned Tijdschr Hematol. 2008;5:221-227
14. Gadisseur AP, van der Meer FJ, Adriaansen HJ, Fihn SD, Rosendaal FR. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol. 2002;117:940-946
15. Fihn SD, Gadisseur AA, Pasterkamp E, et al. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost. 2003;90:260-266
16. Gadisseur AP, Breukink-Engbers WG, van der Meer FJ, van den Besselaar AM, Sturk A, Rosendaal FR. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial. Arch Intern Med. 2003;163:2639-2646
17. Veeger NJ, Piersma-Wichers M, Tijssen JG, Hillege HL, van der Meer J. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol. 2005;128:513-519
18. Veeger NJ, Piersma-Wichers M, Hillege HL, Crijns HJ, van der Meer J. Early detection of patients with a poor response to vitamin K antagonists: the clinical impact of individual time within target range in patients with heart disease. J Thromb Haemost. 2006;4:1625-1627
19. Gadisseur AP, Christiansen SC, Van der Meer FJ, Rosendaal FR. The quality of oral anticoagulant therapy and recurrent venous thrombotic events in the Leiden Thrombophilia Study. J Thromb Haemost. 2007;5:931-936
20. Rombouts EK, Rosendaal FR, Van der Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost. 2007;5:2043-2048
21. Levi M, de Peuter OR, Kamphuisen PW. Management strategies for optimal control of anticoagulation in patients with atrial fibrillation. Sem Thromb Haemost. 2009;35:560-567
22. van Geest-Daalderop JH, Hutten BA, Pequeriaux NC, Levi M, Sturk A. Improvement in the regulation of the vitamin K antagonist acenocoumarol after a standard initial dose regimen: prospective validation of a prescription model. J Thrombolysis. 2009;27:207-214.